Over the past 50 years, a relevant progress has been made toward our understanding of classical Hodgkin lymphoma pathology and cell biology. Histologic classification evolved through different systems to the 2008 World Health Organization classification, upgraded in 2016. Mixed cellularity is a subtype of classical Hodgkin lymphoma characterized by diagnostic HodgkinReed Sternberg cells in a mixed inflammatory background without sclerosis. Mononuclear Hodgkin cells can be present. The mixed cellular background is considered the hallmark of the Mixed cellularity classical Hodgkin lymphoma subtype. In particular, heterogeneous constituents including admixed eosinophils plasma cells, histiocytes and small lymphocytes are usually found. The composition of this background varies greatly.
Identity

Other names
, have lost the expression of most B-cell genes and acquired expression of genes that are typical for other types of hematopoietic and lymphoid cells (Greaves and Gribben 2012; Steidl et al. 2012; Tiacci et al., 2012) . Phenotype Phenotypically, tumour cells of MCcHL are CD30 and CD15 positive (Stein et al., 2008) and exhibit additional expression of the following markers: -Plasma cell markers (MUM1/IRF4) usually positive.
-Molecules involved in Ag presentation (MHC class II, CD40, CD80, CD86) consistently positive. Cellular components of the cHL microenvironment express molecules involved in cancer cell growth and survival (such as CD30L or CD40L), and in immune escape (programmed death 1 (PD-1). A fraction of infiltrating CD4+ T cells are regulatory T (Treg) cells. Treg cells and PD-1+ T cells also interact with HRS cells (Aldinucci et al., 2010; Liu et al., 2014; Carbone et al., 2015) .
Epidemiology
Classical Hodgkin lymphoma is a distinct neoplastic entity with heterogeneous epidemiological features. It accounts for approximately 10% of all malignant lymphomas (Stein et al., 2008) .Classical HL is the most common cancer in patients under 20 years (adolescents and younger adults). The first peak of incidence can be observed in patients under 35 years of age, whereas a second incidence peak can be observed in the elderly (Hjalgrim et al, 2008; Stein et al., 2008) . MCcHL accounts for approximately 20-25% of cHL. MCcHL is more frequent in patients with HIV infection and in resource poor areas. The incidence of MCcHL is more frequent in male than in females and peaks at age 35-40 years.
Cytology
The recognition of MCcHL is based on the presence of diagnostic HRS cells in a specific inflammatory background, the composition of which varies greatly and includes eosinophils, neutrophils, histiocytes and plasma cells. Binucleated and multinucleated HRS cells with bi-or multinucleation and huge nucleoli are pathognomonic for MCcHL identification. 
Pathology
Treatment
Like in other cHL subtypes, cure rates approaching 80% have been achieved in patients undergoing chemo-radiotherapy, qualifying cHL as a chemosensitive disease (Santoro et al., 1987 , Canellos et al., 2014 .
Prognosis
MCcHL exhibit a better prognosis than that of NScHL.
Genetics
Recurrent genetic alterations have been identified in HRS cells of cHL (including MCcHL). These lesions affecting members of the NF-kappaB or JAK/STAT signalling pathways (Küppers and Re, 2007; Hartmann et al., 2008; Steidl et al., 2010; Küppers 2011; Küppers et al., 2012; Pasqualucci and Dalla Favera, 2014) . See also the pertinent section within the CARDS describing the general features of cHL (Küppers, 2011; Carbone and Gloghini, 2016) .
Cytogenetics
Cytogenetics morphological
See the pertinent sections within the CARDS describing the general features of cHL (Küppers, 2011; Carbone and Gloghini, 2016) .
